Gladius Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$23.1M Sell
25,100
-300
-1% -$304K 1.03% 24
2025
Q4
$27.3M Buy
25,400
+12,600
+98% +$12M 1.5% 19
2025
Q3
$9.77M Buy
12,800
+8,300
+184% +$6.18M 1.03% 23
2025
Q2
$3.51M Sell
4,500
-5,100
-53% -$3.96M 1.28% 14
2025
Q1
$7.93M Sell
9,600
-9,300
-49% -$7.74M 2.11% 15
2024
Q4
$14.6M Buy
18,900
+5,000
+36% +$4.14M 1.57% 19
2024
Q3
$12.3M Buy
13,900
+5,900
+74% +$5.3M 1.48% 14
2024
Q2
$7.24M Buy
8,000
+2,300
+40% +$1.84M 0.89% 11
2024
Q1
$4.43M Sell
5,700
-4,100
-42% -$2.92M 1.46% 12
2023
Q4
$5.71M Sell
9,800
-19,300
-66% -$11.3M 0.89% 24
2023
Q3
$15.6M Buy
29,100
+13,500
+87% +$6.96M 0.65% 35
2023
Q2
$7.32M Sell
15,600
-10,600
-40% -$4.45M 0.36% 35
2023
Q1
$9M Buy
26,200
+21,700
+482% +$7.32M 0.52% 41
2022
Q4
$1.65M Sell
4,500
-7,000
-61% -$2.48M 0.12% 52
2022
Q3
$3.72M Buy
11,500
+5,400
+89% +$1.71M 0.16% 54
2022
Q2
$1.98M Buy
6,100
+3,600
+144% +$1.08M 0.1% 73
2022
Q1
$716K Buy
2,500
+500
+25% +$129K 0.05% 86
2021
Q4
$553K Buy
+2,000
New +$507K 0.04% 106

Other funds holding LLY

Gladius Capital Management's LLY Position: Q1 2026 in Review

Gladius Capital Management opened a new position in Eli Lilly (LLY) in Q1 2026: 3,400 shares worth $3.13M. The stake represents 0.14% of the portfolio and ranks #81 among its holdings. This is a return to the name: Gladius Capital Management previously reported a position in LLY as recently as Q3 2025.

Gladius Capital Management first reported a position in LLY in Q4 2021 and has held it in 16 quarters since. The position peaked at $6.09M in Q4 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Gladius Capital Management held 3,400 shares of Eli Lilly worth $3.13M as of Q1 2026.
  • Eli Lilly was a new Gladius Capital Management position in Q1 2026.
  • Eli Lilly made up 0.14% of Gladius Capital Management's portfolio in Q1 2026, its #81 holding.
  • Gladius Capital Management first reported a position in Eli Lilly in Q4 2021 and has held it in 16 quarters since.
  • Gladius Capital Management's Eli Lilly position peaked at $6.09M in Q4 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Gladius Capital Management's 13F filing for Q1 2026, filed 7 May 2026.